Malaga, Jul 14 (EFE).- The Malaga Regional is one of the eight Spanish hospitals that will participate in a trial by the pharmaceutical company Hipra to study the combination of its vaccine against covid-19, Bimervax, and one for the flu .
The study aims to evaluate the safety and immune response of Bimervax when co-administered (one in each arm) with the seasonal flu vaccine in adults over 65 years of age who were vaccinated for the first time against covid with a vaccine of messenger RNA.
As reported this Friday by the Regional Hospital in a statement, the recruitment of patients to participate in this clinical trial has already begun, which has been authorized by the Spanish Agency for Medicines and Health Products (AEMPS).
The study will have the participation of 300 volunteers and will be carried out in seven more hospitals in Spain: Hospital Clínic Barcelona (Barcelona), Hospital Dr. Josep Trueta (Girona), Hospital Germans Trias i Pujol (Badalona), Hospital Clínico Universitario de Valladolid (Valladolid), HM Modelo (A Coruña), Hospital de Santiago (Santiago de Compostela) and CAP Centelles (Centelles, Barcelona).
Covid-19 and seasonal flu are respiratory illnesses that are transmitted from person to person mainly through droplets from the nose or mouth, and while most people experience both mildly, they can become serious.
The vaccines that will be used in this study are already authorized to prevent these diseases, and both their safety and efficacy have been tested and described, but in order to be able to administer them together in the future, it is necessary to verify the safety and the immune response that has the combined administration, he explained.
The clinical trial will last two months in which each volunteer will have to go to the hospital three times. Those interested can register by email: [email protected].
The 300 participants will be divided into three groups at random, so that the first will receive a dose of the flu vaccine and a dose of placebo in the other arm; the second will receive a dose of Bimervax and a placebo, and the third will be vaccinated with a dose of the flu vaccine and a dose of the covid vaccine.
Volunteers who receive a dose of the flu vaccine will already be protected against this disease for the upcoming 2023/2024 season.
The Bimervax vaccine is kept at a refrigerated temperature, between 2 and 8 degrees, which facilitates its logistics and distribution, and it is not necessary to reconstitute it before use.EFE
mdr/avl
2023-07-14 14:05:01
#Malaga #Regional #study #combination #Hipra #vaccine #flu #Vanguardia
